Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by TH1902on Jul 14, 2022 11:47pm
179 Views
Post# 34825925

RE:The list

RE:The listGood post, the company imo has lost a lot of investors due to mgmt mis-steps in recent years.  Could today's news be the start of something that brings investors back, we will see I suppose.  Macro environment has also played a large role in where the sp currently resides.  We need continued good news and a strong effort by IR to tell the story.  Let's see if a deal comes to fruition soon, that would definitely bring interest.  The Marathon deal is very, very meaningful, what do they know??? 
scarlet1967 wrote:

Since THTX has been keeping their low profile as an investor loyal for over a decade I have been checking on various stuff on regular basis the list below and obviously the net.
Now my simple question is why does an investor has to go so far to gather information about their investment?
Yes one has to do the DD but isn't it the company's responsibility to keep their investors informed on regular basis so they know what the heck is going on?
How would they get much broader  audience if their communication is limited to their own social media? Again today they gave us good news about the early results from the oncology trial which is significant as most of these patients have been treated well below the therapeutic window of the PDC yet despite all odds they have early signs of efficacy and a well tolerated dose so far. Even so Egrifta has been commercialized for a decade the sales are growing. They seem to have managed keeping costs down, secured additional financing deal, Trogarzo IV/IM trials are progressing well list and not last the NASH asset is ready to be initiated so how is that we get single digit appreciation from multi year low valuation? Am I missing something or is the company?
How can one solve a problem if they can't see it? How can you start making all the right moves if you think you already have? I think there are so many opportunities a head of this company but it seems the market doesn't!
Who is supposed to fix it? The journalists?
 



<< Previous
Bullboard Posts
Next >>